

Program Day 1 – Morning

MONDAY – MAY 13, 2019

8:00

Registration and Breakfast

9:00

Opening of the Conference

9:15

Scientific Introduction
Parkinson's Disease

Targeting LRRK2 in Parkinson's disease

Andrew West Duke Center for Neurodegeneration
Research, USA

09:45 – 10:45

PD Model

*Animal models of α -synucleinopathy for Parkinson's disease
drug development*

James Koprich Atuka, Canada

tbd

tbd

PD Disease
Mechanism

*Animal Models and Mechanisms of LRRK2 and VPS35 in Parkinson's
Disease*

Darren Moore Van Andel Research Institute, USA

Pannel Q&A of Session Speakers

Chair: Andrew West, Duke Center for Neurodegeneration Research, USA

10:45

Coffee Break

Exhibition & Poster Session (all Presenters will be at their Posters for Discussion)

12:00 – 13:00

PD Disease
Mechanism

*Protecting synapses will rescue neurons and likely reverse PD symptoms
and progress*

Walter J. Schulz-Schaeffer Neuropathology,
University of the Saarland

PD Drug
Discovery

*Modulation of α -synuclein aggregation in cell models using
small molecules*

Tiago Outeiro Exp. Neurodegeneration, University
of Göttingen, Germany

*Using computer modeling to accelerate drug discovery for Parkinson's
disease: Insights from genetics and transcriptomics*

Spring Behrouz NeuroInitiative, Jacksonville, USA

Pannel Q&A of Session Speakers

Chair: Andrew West, Duke Center for Neurodegeneration Research, USA

13:00

Lunch

Program Day 1 – Afternoon

MONDAY – MAY 13, 2019

14:00		
Scientific Introduction Alzheimer's Disease	<i>The search for alternative β-secretases</i>	Hans-Ulrich Demuth Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany
14:30 – 15:30		
AD Disease Mechanism	<i>Post-translational modifications of Aβ peptides in distinct aggregation pathways and the progression of Alzheimer's disease</i>	Jochen Walter University of Bonn Medical Center, Bonn, Germany
AD Drug Discovery	<i>IsoAspartate-Aβ specific antibody attenuates Alzheimer's Disease-like pathology in transgenic mice</i>	Stephan Schilling Fraunhofer-Institut für Zelltherapie und Immunologie, Halle, Germany
Neurodegeneration Model	<i>Generation and characterization of a human tau knock-in mouse</i>	Holger Cynis Fraunhofer-Institut für Zelltherapie und Immunologie, Halle, Germany
Pannel Q&A of Session Speakers Chair: Hans-Ulrich Demuth, Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany		
15:30		
Coffee Break Exhibition & Poster Session (all Presenters will be at their Posters for Discussion) One on One Meetings		
16:45 – 18:00		
AD Model	<i>An in vivo Tau seeding and spreading model in mice</i>	Bart Roucourt Remynd, Leuven, Belgium
AD Drug Discovery	<i>Elimination of Aβ oligomers by PRI-002 reverses cognition deficits and decelerates neurodegeneration</i>	Dieter Willbold Priavoid, Jülich, Germany
	<i>Repurposing of igmesine for neuroprotection: effects in Alzheimer's and other neurodegenerative diseases</i>	François J. Roman SigmaThera, France
	<i>PBD-CO6, an anti-pyroglutamate-3 Aβ antibody for immunotherapy against Alzheimer's Disease</i>	Thore Hettmann probiodrug, Germany
Pannel Q&A of Session Speakers Chair: Hans-Ulrich Demuth, Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany		
18:00		
Wine Tasting Vinemaker Sommer, Siefersheim, Germany		
19:00 – 22:00		
Dinner Rheinhessen offers many fine cuisines. We will enjoy a surprise three course gourmet menu from Philipp Stein (One Star Guide Michelin) in the hotel restaurant, accompanied by fitting local wines.		
END OF THE FIRST DAY		

Program Day 2 – Morning

TUESDAY – MAY 14, 2019

8:00

Joint Breakfast
 Exhibition
 Poster Visits

8:30

Scientific Introduction

Prion-like spreading of cross-seeded protein aggregates

Rakez Kayed Departments of Neurology & Neuroscience & Cell Biology & Anatomy, University of Texas, USA

9:00 – 10:00

Prion-Mechanism

Prion-like propagation in systemic amyloidosis

Marcus Fändrich Protein Biochemistry, Ulm University, Germany

ALS Drug Discovery

D-enantiomeric peptides for the treatment of ALS

Antje Willoweit Inst. F. Neurosciences & Medicine, Jülich, Germany

FTD Drug Discovery

tbd

tbd

Pannel Q&A of Session Speakers

Chair: Rakez Kayed, University of Texas, USA

10:00

Coffee Break
 Exhibition & Poster Session (all Presenters will be at their Posters for Discussion)
 One on One Meetings

11:00

Drug Discovery

Using small molecules for stimulation of endogeneous stem cells for treatment of neurodegenerative diseases

Georg C. Terstappen CSO at OxStem, Oxford, UK

11:20

Cognition Models

Back to the future: The importance of cognitive preclinical models for Alzheimer's disease

Joseph Araujo InterVivo Solutions, Toronto, Canada

11:40

Cognition Models

Using machine learning approaches to identify symptomatic treatments for neurodegenerative diseases

Emer Leahy Psychogenics, New York City, USA

12:00

Lunch

Program Day 2 – Afternoon

TUESDAY – MAY 14, 2019

13:00		
Current State of Drug Discovery in Neurodegenerative Diseases	<i>A role for mutant ubiquitin in amyloid-β seeding?</i>	Fred van Leeuwen Maastricht, Maastricht University, The Netherlands
13:30		
Clinical Development in Neurodegenerative Diseases	<i>tbd</i>	<i>tbd</i>
14:00		
Coffee Break Exhibition and Posters (all Presenters will be at their Posters for Discussion) One on One Meetings		
15:00		
Pannel Discussion: What are the new joint approaches of drug discovery companies and service providers to reach translational drug discovery in neurodegenerative disease <i>Participants: Pharma, Biotech, and Service Providers</i>		
16:00 – 16:15		
Summary and wrap-up of the conference		
END OF THE CONFERENCE AND DEPARTURE		